- Starboard Value has amassed a roughly $1 billion stake in drugmaker Pfizer, according to people familiar with the matter.
- The activist fund run by Jeff Smith is looking to tap former Pfizer CEO Ian Read and ex-finance chief Frank D'Amelio, although it is unclear in what capacity.
- Starboard's stake comes amid a time of serious struggle at the drugmaker, which has begun to cut costs aggressively as demand for its Covid-19 medicines continues to recede.
Activist investor Starboard Value has a roughly $1 billion stake in pharmaceutical giant Pfizer and is seeking to mount a turnaround at the struggling company, according to people familiar with the matter.
The activist's exact plans could not be learned, but Starboard has approached former Pfizer CEO Ian Read and ex-finance chief Frank D'Amelio, both of whom have expressed interest in supporting Starboard's turnaround, said the people.
Starboard believes that Pfizer's current leadership under CEO Albert Bourla has stepped away from its historically disciplined cost structure and investment in novel drugs, said the people, who requested anonymity to discuss confidential information freely.
Get top local stories in Southern California delivered to you every morning. Sign up for NBC LA's News Headlines newsletter.
Pfizer's revenue and free cash flow ballooned during the Covid-19 pandemic, thanks to the company's fast-tracked vaccine. But its stock has not done well, trading about 30% lower than it did in 2019. That is in part due to an expensive acquisition strategy — nearly $70 billion in M&A since 2020 — the return of which some analysts have questioned.
One particularly concerning deal was Pfizer's acquisition of Global Blood Therapeutics. Pfizer pulled a drug for sickle cell disease it got just two years ago via the roughly $5 billion acquisition. The company played down the financial impact in September, saying the drug, Oxbryta, brought in a little more than $300 million last year.
Read was Pfizer's chief from 2010 to 2019 and inherited a company in tumult. But Pfizer shares more than doubled during his tenure, as executives instituted that cost- and core-focused culture which it has now apparently moved from.
Money Report
To be sure, the company has taken steps to tamp down on costs. It began a $4 billion cost-cutting program and then announced a second round of further reductions. Still, more than $100 billion in shareholder value has evaporated since the Covid-19 pandemic faded largely into the rearview mirror.
Starboard is run by Jeff Smith, and has historically focused on the technology sector. It is currently challenging News Corp's dual-class share structure, and in recent months has mounted campaigns at Autodesk, Salesforce and Match Group.
The Wall Street Journal earlier reported news of Starboard's stake. A Pfizer spokesperson declined to comment on "speculation and rumor."
— CNBC's Angelica Peebles contributed to this report.
